

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/008,901		12/07/2001	Perry F. Renshaw	04843-033001 / MCL 1779.1	7202	
26161	7590	07/02/2003				
FISH & RI		SON PC	EXAMINER			
225 FRANK BOSTON, N		0		SHARAREH, SHAHNAM J		
				ART UNIT	PAPER NUMBER	
				1617		
				DATE MAILED: 07/02/2003	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

·		Applicati n No.	Applicant(s)					
		10/008,901	RENSHAW ET AL.					
	Office Action Summary	Examiner	Art Unit					
		Shahnam Sharareh	1617					
	Th MAILING DATE of this communication appears on the c ver sh t with the corresp ndence address Peri d for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1)🖂	Responsive to communication(s) filed on <u>07 L</u>	<u>December 2001</u> .						
2a)□	This action is <b>FINAL</b> . 2b) ☐ Th	is action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disp sition of Claims								
4) Claim(s) 1-26 is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.							
6)□	S) Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.							
8)⊠	8) Claim(s) 1-26 are subject to restriction and/or election requirement.							
Application Papers								
9)☐ The specification is objected to by the Examiner.								
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12)☐ The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)[	a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the partified expise pet received.								
* See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)					
U.S. Patent and Tr PTO-326 (Rev		tion Summary	Part of Paper No. 5					

Application/Control Number: 10/008,901 Page 2

Art Unit: 1617

## Election/R strictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-20, drawn to methods of diagnosing a membrane fluidity-related disorder by obtaining a first and second proton relaxation measurement and then comparing the values, classified in class 424, subclass 9.3 or class 600, subclass 410.
- II. Claims 21-24, drawn to methods of assessing the effectiveness of a neurological or psychiatric treatment comprising comparing the different between two measurements of proton relaxation measurement, classified in class 424, subclass 9.3, class 600, subclass 410 and the class or subclass of neurological or psychiatric treatment.
- III. Claim 25, drawn to methods of assessing effectiveness of a neurological treatment comprising comparing a pre-treatment challenge result with a post-treatment challenge result, classified in class 424, subclass 9.3, class 600, subclass 410 and the class, subclass of neurological or psychiatric treatments of pre-and post-treatment challenge.
- IV. Claim 26, drawn to methods of diagnosing a membrane fluidity-related disorder by establishing a test value and comparing the test value with a predetermined range, classified in class 424, subclass 9.3; class 600, subclass 410.

The inventions are distinct, each from the other because of the following reasons:

.,

ř

Application/Control Number: 10/008,901

**Art Unit: 1617** 

Inventions I -IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together and each invention have different modes of operation and provide different effects.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Claims 1-26 are generic to a plurality of disclosed patentably distinct species comprising

- □ Various types of disorders as set forth in claims 2-5,
- Various types of challenges as set forth in claims 6-9.
- Various types of animals including a human as set forth in claims 1, 20-23,
   25-26.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/008,901

**Art Unit: 1617** 

A telephone call was made to June 26, 2003 on Peter Fasse to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shahnam Sharareh whose telephone number is 703-306-5400. The examiner can normally be reached on 8:30 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, PhD can be reached on 703-308-1877. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1123.

Application/Control Number: 10/008,901

Art Unit: 1617

Shannam Sharareh, PharmD Patent Examiner, Art Unit 1617

Page 5

ss June 27, 2003